NKGN (NKGen Biotech) ROE % Adjusted to Book Value : Negative Equity% (As of Sep. 2024)

View and export this data going back to 2023. Start your Free Trial

What is NKGen Biotech ROE % Adjusted to Book Value?

NKGen Biotech's ROE % for the quarter that ended in Sep. 2024 was Negative Equity. NKGen Biotech's PB Ratio for the quarter that ended in Sep. 2024 was N/A. NKGen Biotech's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was Negative Equity.

NKGen Biotech ROE % Adjusted to Book Value Historical Data

The historical data trend for NKGen Biotech's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NKGen Biotech ROE % Adjusted to Book Value Chart

NKGen Biotech Annual Data

Trend

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

NKGen Biotech Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial					-	-	-	-	Negative Equity

Competitive Comparison of NKGen Biotech's ROE % Adjusted to Book Value

For the Biotechnology subindustry, NKGen Biotech's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NKGen Biotech's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NKGen Biotech's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where NKGen Biotech's ROE % Adjusted to Book Value falls into.

NKGen Biotech ROE % Adjusted to Book Value Calculation

NKGen Biotech's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	0.00%	/	N/A
	=	N/A

NKGen Biotech's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	Negative Equity	/	N/A
	=	Negative Equity

NKGen Biotech ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of NKGen Biotech's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

NKGen Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NKGen Biotech Inc (OTCPK:NKGN) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

3001 Daimler Street, Santa Ana, CA, USA, 92705

Website

https://www.nkgenbiotech.com

NKGen Biotech Inc is a biotechnology company developing cell therapies for neurodegenerative and oncological diseases based on activated NK cells. NK cells are part of the human innate immune response system that can selectively identify and destroy abnormal or diseased cells. Its product candidates are based on a proprietary manufacturing and cryopreservation process that produces SuperNKTM (SNK) cells that have shown increased activity as compared to the starting population of NK cells, based on the results of in vitro experiments performed by NKMAX, as defined by parameters such as cytotoxicity, cytokine production and activating receptor expression. SNK cells can be produced in large quantities and cryopreserved while maintaining high levels of cytotoxicity.